Last reviewed · How we verify

RANITIDINE BISMUTH CITRATE

FDA-approved approved Small molecule ✓ Verified May 2026 Quality 5/100

RANITIDINE BISMUTH CITRATE is a drug. It is currently FDA-approved (first approved 1996).

Ranitidine bismuth citrate is a small molecule that acts as a histamine H2 receptor antagonist. It has been studied in various clinical trials for conditions such as laryngopharyngeal reflux and arthritis knee, among others.

At a glance

Generic nameRANITIDINE BISMUTH CITRATE
ModalitySmall molecule
PhaseFDA-approved
First approval1996

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about RANITIDINE BISMUTH CITRATE

What is RANITIDINE BISMUTH CITRATE?

RANITIDINE BISMUTH CITRATE is a Small molecule drug.

When was RANITIDINE BISMUTH CITRATE approved?

RANITIDINE BISMUTH CITRATE was first approved on 1996.

What development phase is RANITIDINE BISMUTH CITRATE in?

RANITIDINE BISMUTH CITRATE is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing